

# Early PET Predictive in Barrett-Related Cancer

BY BRUCE JANCIN  
Denver Bureau

COLORADO SPRINGS — The early metabolic response to induction chemotherapy as assessed by fluorodeoxyglucose-PET just 2 weeks into the treatment of patients with locally advanced Barrett cancer reliably distinguishes those who will have low recurrence and favorable long-term survival post resection from those with a poor prognosis, Dr. Joerg R. Siewert said

at the annual meeting of the American Surgical Association. “This suggests FDG-PET can be used to tailor treatment according to the chemosensitivity of tumors. Early response evaluation after induction chemotherapy opens the door to a more individualized therapy in Barrett’s cancer,” added Dr. Siewert, professor and chairman of surgery at Technical University of Munich. Patients without a metabolic response after the first 2 weeks can be spared the mor-

bidity and expense of the remaining 10 weeks of the course of chemotherapy, since they are unlikely to benefit from it, he said. Dr. Siewert reported on 104 patients with locally advanced adenocarcinoma of the esophagus or esophagogastric junction who had a baseline FDG-PET and then were placed on induction chemotherapy before planned tumor resection. After 2 weeks of chemotherapy they had a second FDG-PET, at which point 48% were classified as responders based on at least a 35%

reduction in tumor metabolic activity. Responders continued on chemotherapy for 10 more weeks before resection, whereas nonresponders stopped chemotherapy and had palliative surgery based on prior studies indicating that further chemotherapy would be of little benefit. Curative R0 resection was achieved in 96% of responders, compared with 74% of nonresponders. Overall, 20% of responders and 62% of nonresponders had lymph node involvement. Of early metabolic responders, 58% experienced major histologic remission after resection, as did none of the nonresponders. The distant recurrence rate was 16% in responders, compared with 29% in nonresponders. Median overall survival was more than 5 years in responders and less than 26 months in nonresponders. Induction chemotherapy did not adversely affect surgical risk. Postoperative complications occurred in 34% of patients



‘Early response evaluation ... opens the door to a more individualized therapy.’  
DR. SIEWERT

and in-hospital mortality in 2%, with similar rates in the two groups. The superior survival in the PET-defined early metabolic responders can probably be explained by their more radical resectability and more favorable lymph node-based tumor staging, according to Dr. Siewert. Discussant Dr. Murray F. Brennan, chairman of surgery at Memorial Sloan-Kettering Cancer Center, New York, noted that the patients in Dr. Siewert’s study were classified as AEG I/II. In Dr. Brennan’s own work with AEG III patients having subcardial gastric cancer, he has been unable to show any prognostic significance for an early metabolic response at 2 weeks. Instead, he sees a prognostic value only when FDG-PET is done after 30 days of chemotherapy and at a threshold of at least a 50% reduction in tumor metabolic activity. Dr. Siewert replied that he, too, observed a difference in the early prognostic value of PET between AEG I/II and III patients. Audience members asked how Dr. Siewert manages the early PET nonresponders, given their poor outcomes in this trial. He replied that it’s an open question. In another study, he gave early nonresponders a course of chemoradiation, but few responded. “It’s easy to treat the responders. They are always the winners,” Dr. Siewert observed. “The problem is how to treat the nonresponders. I have a feeling that it’s not a good idea to change to chemoradiation, because the preliminary results are not promising. For the moment, I think the best treatment option for the nonresponders is still palliative surgical resection, but we have to wait for further trials to make definitive statements.” All papers presented at the 127th annual meeting of the ASA are submitted to the Annals of Surgery for consideration. ■



**omeprazole/sodium bicarbonate**  
**Brief Summary of Prescribing Information**  
**INDICATIONS AND USAGE**  
**Duodenal Ulcer**  
ZEGERID is indicated for short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.  
**Gastric Ulcer**  
ZEGERID is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. (See CLINICAL PHARMACOLOGY, Clinical Studies, Gastric Ulcer.)  
**Treatment of Gastroesophageal Reflux Disease (GERD)**  
**Symptomatic GERD**  
ZEGERID is indicated for the treatment of heartburn and other symptoms associated with GERD.  
**Erosive Esophagitis**  
ZEGERID is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)  
The efficacy of ZEGERID used for longer than 8 weeks in these patients has not been established. In the rare instance of a patient not responding to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. If there is recurrence of erosive esophagitis or GERD symptoms (eg, heartburn), additional 4-8 week courses of omeprazole may be considered.  
**Maintenance of Healing of Erosive Esophagitis**  
ZEGERID is indicated to maintain healing of erosive esophagitis. Controlled studies do not extend beyond 12 months.  
**Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients**  
ZEGERID Powder for Oral Suspension 40 mg/1680 mg is indicated for the reduction of risk of upper GI bleeding in critically ill patients.  
**CONTRAINDICATIONS**  
ZEGERID is contraindicated in patients with known hypersensitivity to any components of the formulation.  
**PRECAUTIONS**  
**General**  
Symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy.  
Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole.  
Each ZEGERID Capsule contains 1100 mg (13 mEq) of sodium bicarbonate (equivalent to 300 mg of Na+). Each packet of ZEGERID Powder for Oral Suspension contains 1680 mg (20 mEq) of sodium bicarbonate (equivalent to 460 mg of Na+).  
The sodium content of ZEGERID products should be taken into consideration when administering to patients on a sodium restricted diet. Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. Sodium bicarbonate should be used with caution in patients with Bartter's syndrome, hypokalemia, respiratory alkalosis, and problems with acid-base balance. Long-term administration of bicarbonate with calcium or milk can cause milk-alkali syndrome.  
**Information for Patients**  
ZEGERID should be taken on an empty stomach at least one hour prior to a meal.  
ZEGERID is available either as 40 mg or 20 mg capsules with 1100 mg sodium bicarbonate. ZEGERID is also available either as 40 mg or 20 mg single-dose packets of powder for oral suspension with 1680 mg sodium bicarbonate.  
**Directions for Use:**  
Capsules: Swallow intact capsule with water. DO NOT USE OTHER LIQUIDS. DO NOT OPEN CAPSULE AND SPRINKLE CONTENTS INTO FOOD.  
Powder for Oral Suspension: Empty packet contents into a small cup containing 1-2 tablespoons of water. DO NOT USE OTHER LIQUIDS OR FOODS. Stir well and drink immediately. Refill cup with water and drink.  
**Drug Interactions**  
Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time. Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized by the cytochrome P-450 system (eg, cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with ZEGERID.  
Because of its profound and long-lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). In the clinical efficacy trials, antacids were used concomitantly with the administration of omeprazole. Concomitant administration of omeprazole and atazanavir has been reported to reduce the plasma levels of atazanavir. Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus.  
Co-administration of omeprazole and clarithromycin have resulted in increases of plasma levels of omeprazole, clarithromycin, and 14-hydroxy-clarithromycin (see also CLINICAL PHARMACOLOGY, Pharmacokinetics).  
**Carcinogenesis, Mutagenesis, Impairment of Fertility**  
In two 24-month carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44.0 and 140.8 mg/kg/day (approximately 0.5 to 28.5 times the human dose of 40 mg/day, based on body surface area) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole. Gastric carcinoids seldom occur in the untreated rat. In addition, ECL cell hyperplasia was present in all treated groups of both sexes. In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (approximately 2.8 times the human dose of 40 mg/day, based on body surface area) for one year, then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell hyperplasia was observed at the end of one year (94% treated vs 10% controls). By the second year the difference between treated and control rats was much smaller (46% vs 26%) but still showed more hyperplasia in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for two years. For this strain of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. In a 52-week toxicity study in Sprague-Dawley rats, brain astrocytomas were found in a small number of males that received omeprazole at dose levels of 0.4, 2, and 16 mg/kg/day (about 0.1 to 3.3 times the human dose of 40 mg/day, based on body surface area). No astrocytomas were observed in female rats in this study. In a 2-year carcinogenicity study in Sprague-Dawley rats, no astrocytomas were found in males and females at the high dose of 140.8 mg/kg/day (about 28.5 times the human dose of 40 mg/day, based on body surface area). A 78-week mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive. A 26-week P53 (+/-) transgenic mouse carcinogenicity study was not positive. Omeprazole was positive for clastogenic effects in an *in vitro* human lymphocyte chromosomal aberration assay, in one of two *in vivo* mouse micronucleus tests, and in an *in vivo* bone marrow cell chromosomal aberration assay. Omeprazole was negative in the *in vitro* Ames Test, an *in vitro* mouse lymphoma cell forward mutation assay and an *in vivo* rat liver DNA damage assay. Omeprazole at oral doses up to 138 mg/kg/day (about 28 times the human dose of 40 mg/day, based on body surface area) was found to have no effect on the fertility and general reproductive performance in rats.  
**Pregnancy**  
**Pregnancy Category C**  
There are no adequate and well-controlled studies on the use of omeprazole in pregnant women. The vast majority of reported experience with omeprazole during human pregnancy is first trimester exposure and the duration of use is rarely specified, e.g., intermittent vs. chronic. An expert review of published data on experiences with omeprazole use during pregnancy by TERIS—the Teratogen Information System—concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as fair).<sup>1</sup>  
Three epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy to the frequency of abnormalities among infants of women exposed to H2-receptor antagonists or other controls. A population-based prospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy.<sup>2</sup> In utero exposure to omeprazole was not associated with increased risk of any malformation (odds ratio 0.82, 95% CI 0.50-1.34), low birth weight or low Apgar score. The number of infants born with

ventricular septal defects and the number of stillborn infants was slightly higher in the omeprazole exposed infants than the expected number in the normal population. The author concluded that both effects may be random.  
A retrospective cohort study reported on 689 pregnant women exposed to either H2-blockers or omeprazole in the first trimester (134 exposed to omeprazole).<sup>3</sup> The overall malformation rate was 4.4% (95% CI 3.6-5.3) and the malformation rate for first trimester exposure to omeprazole was 3.6% (95% CI 1.5-8.1). The relative risk of malformations associated with first trimester exposure to omeprazole compared with nonexposed women was 0.9 (95% CI 0.3-2.2). The study could effectively rule out a relative risk greater than 2.5 for all malformations. Rates of preterm delivery or growth retardation did not differ between the groups.  
A controlled prospective observational study followed 113 women exposed to omeprazole during pregnancy (89% first trimester exposures).<sup>4</sup> The reported rates of major congenital malformations was 4% for the omeprazole group, 2% for controls exposed to nonteratogens, and 2.8% in disease-paired controls (background incidence of major malformations 1-5%). Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean birth weight did not differ between the groups. The sample size in this study has 80% power to detect a 5-fold increase in the rate of major malformation.  
Several studies have reported no apparent adverse short term effects on the infant when single dose oral or intravenous omeprazole was administered to over 200 pregnant women as premedication for cesarean section under general anesthesia.  
Teratology studies conducted in pregnant rats at doses up to 138 mg/kg/day (about 28 times the human dose of 40 mg/day, based on body surface area) and in pregnant rabbits at doses up to 69 mg/kg/day (about 28 times the human dose of 40 mg/day, based on body surface area) did not disclose any evidence for a teratogenic potential of omeprazole.  
In rabbits, omeprazole in a dose range of 6.9 to 69 mg/kg/day (about 2.8 to 28 times the human dose of 40 mg/day, based on body surface area) produced dose-related increases in embryolethality, fetal resorptions and pregnancy disruptions. In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138.0 mg/kg/day (about 2.8 to 28 times the human dose of 40 mg/day, based on body surface area).  
Chronic use of sodium bicarbonate may lead to systemic alkalosis and increased sodium intake can produce edema and weight increase. There are no adequate and well-controlled studies in pregnant women. Because animal studies and studies in humans cannot rule out the possibility of harm, omeprazole should be used during pregnancy only if the potential benefit to pregnant women justifies the potential risk to the fetus.  
**Nursing Mothers**  
Omeprazole concentrations have been measured in breast milk of a woman following oral administration of 20 mg. The peak concentration of omeprazole in breast milk was less than 7% of the peak serum concentration. The concentration will correspond to 0.004 mg of omeprazole in 200 mL of milk. Because omeprazole is excreted in human milk, because of the potential for serious adverse reactions in nursing infants from omeprazole, and because of the potential for tumorigenicity shown for omeprazole in rat carcinogenicity studies, a decision should be taken to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. In addition, sodium bicarbonate should be used with caution in nursing mothers.  
**Pediatric Use**  
Clinical studies have been conducted evaluating delayed-release omeprazole in pediatric patients. There are no adequate and well-controlled studies in pediatric patients with ZEGERID.  
**Geriatric Use**  
Omeprazole was administered to over 2000 elderly individuals (≥ 65 years of age) in clinical trials in the U.S. and Europe. There were no differences in safety and effectiveness between the elderly and younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.  
Pharmacokinetic studies with buffered omeprazole have shown the elimination rate was somewhat decreased in the elderly and bioavailability was increased. The plasma clearance of omeprazole was 250 mL/min (about half that of young subjects). The plasma half-life averaged one hour, about the same as that in nonelderly, healthy subjects taking ZEGERID. However, no dosage adjustment is necessary in the elderly. (See CLINICAL PHARMACOLOGY.)  
**ADVERSE REACTIONS**  
Omeprazole was generally well tolerated during domestic and international clinical trials in 3096 patients.  
In the U.S. clinical trial population of 465 patients, the adverse experiences summarized in Table 11 were reported to occur in 1% or more of patients on therapy with omeprazole. Numbers in parentheses indicate percentages of the adverse experiences considered by investigators as possibly, probably or definitely related to the drug.  

	Omeprazole (n = 465)	Placebo (n = 64)	Ranitidine (n = 195)
Headache	6.9 (2.4)	6.3	7.7 (2.6)
Diarrhea	3.0 (1.9)	3.1 (6.2)	2.1 (0.5)
Abdominal Pain	2.4 (0.4)	3.1	2.1
Nausea	2.2 (0.9)	3.1	4.1 (0.5)
URI	1.9	2.6	2.9
Dizziness	1.5 (0.6)	0.0	2.6 (1.0)
Vomiting	1.5 (0.4)	4.7	1.5 (0.5)
Rash	1.5 (1.1)	0.0	0.0
Constipation	1.1 (0.9)	0.0	0.0
Cough	1.1	0.0	1.5
Asthenia	1.1 (0.2)	1.6 (1.6)	1.5 (1.0)
Back Pain	1.1	0.0	0.5

  
Table 12 summarizes the adverse reactions that occurred in 1% or more of omeprazole-treated patients from international double-blind, and open-label clinical trials in which 2,631 patients and subjects received omeprazole.  

	Omeprazole (n = 2631)	Placebo (n = 120)
Body as a Whole, site unspecified		
Abdominal pain	5.2	3.3
Asthenia	1.3	0.8
Digestive System		
Constipation	1.5	0.8
Diarrhea	3.7	2.5
Flatulence	2.7	5.8
Nausea	4.0	6.7
Vomiting	3.2	10.0
Acid regurgitation	1.9	3.3
Nervous System/Psychiatric		
Headache	2.9	2.5

  
A controlled clinical trial conducted in 359 critically ill patients, comparing ZEGERID 40 mg/1680 mg suspension once daily to I.V. cimetidine 1200 mg/day for up to 14 days. The incidence and total number of AEs experienced by ≥ 3% of patients in either group are presented in Table 13 by body system and preferred term.  

	ZEGERID® (N=178)	Cimetidine (N=181)
Med/DRA		
Body System	All AEs (n %)	All AEs (n %)
Preferred Term		
BLOOD AND LYMPHATIC SYSTEM DISORDERS		
Anaemia NOS	14 (7.9)	14 (7.7)
Anaemia NOS Aggravated	4 (2.2)	7 (3.9)
Thrombocytopenia	18 (10.1)	11 (6.1)
CARDIAC DISORDERS		
Atrial Fibrillation	11 (6.2)	7 (3.9)
Bradycardia NOS	7 (3.9)	5 (2.8)
Supraventricular Tachycardia	6 (3.4)	2 (1.1)
Tachycardia NOS	6 (3.4)	6 (3.3)
Ventricular Tachycardia	8 (4.5)	6 (3.3)
GASTROINTESTINAL DISORDERS*		
Constipation	8 (4.5)	8 (4.4)
Diarrhoea NOS	7 (3.9)	15 (8.3)

Gastric Hypomotility	3 (1.7)	6 (3.3)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS		
Hyperpyrexia	8 (4.5)	3 (1.7)
Oedema NOS	5 (2.8)	11 (6.1)
Pyrexia	36 (20.2)	29 (16.0)
INFECTIONS AND INFESTATIONS		
Candidal Infection NOS	3 (1.7)	7 (3.9)
Oral Candidiasis	7 (3.9)	1 (0.6)
Sepsis NOS	9 (5.1)	9 (5.0)
Urinary Tract Infection NOS	4 (2.2)	6 (3.3)
INVESTIGATIONS		
Liver Function Tests NOS Abnormal	3 (1.7)	6 (3.3)
METABOLISM AND NUTRITION DISORDERS		
Fluid Overload	9 (5.1)	14 (7.7)
Hyperpycaemia NOS	19 (10.7)	21 (11.6)
Hyperkalaemia	4 (2.2)	6 (3.3)
Hypernatraemia	3 (1.7)	9 (5.0)
Hypocalcaemia	11 (6.2)	10 (5.5)
Hypoglycaemia NOS	6 (3.4)	8 (4.4)
Hypokalaemia	22 (12.4)	24 (13.3)
Hypomagnesaemia	18 (10.1)	18 (9.9)
Hyponatremia	7 (3.9)	5 (2.8)
Hypophosphataemia	11 (6.2)	7 (3.9)
PSYCHIATRIC DISORDERS		
Agitation	6 (3.4)	16 (8.8)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS		
Acute Respiratory Distress Syndrome	6 (3.4)	7 (3.9)
Nosocomial Pneumonia	20 (11.2)	17 (9.4)
Pneumothorax NOS	1 (0.6)	8 (4.4)
Respiratory Failure	3 (1.7)	6 (3.3)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS		
Decubitus Ulcer	6 (3.4)	5 (2.8)
Rash NOS	10 (5.6)	11 (6.1)
VASCULAR DISORDERS		
Hypertension NOS	14 (7.9)	6 (3.3)
Hypotension NOS	17 (9.6)	12 (6.6)

\*Clinically significant UGI Bleeding was considered an SAE but it is not included in this table.  
Additional adverse experiences occurring in < 1% of patients or subjects in domestic and/or international trials conducted with omeprazole, or occurring since the drug was marketed, are shown below within each body system. In many instances, the relationship to omeprazole was unclear.  
**Body As a Whole**  
Allergic reactions, including, rarely, anaphylaxis (see also Skin below), fever, pain, fatigue, malaise, abdominal swelling.  
**Cardiovascular**  
Chest pain or angina, tachycardia, bradycardia, palpitation, elevated blood pressure, and peripheral edema.  
**Gastrointestinal**  
Mild and, rarely, marked elevations of liver function tests [ALT (SGPT), AST (SGOT), γ-glutamyl transpeptidase, alkaline phosphatase, and bilirubin (jaundice)]. In rare instances, overt liver disease has occurred, including hepatocellular, cholestatic, or mixed hepatitis, liver necrosis (some fatal), hepatic failure (some fatal), and hepatic encephalopathy.  
**Metabolic/Nutritional**  
Hyponatremia, hypoglycemia, and weight gain.  
**Musculoskeletal**  
Muscle cramps, myalgia, muscle weakness, joint pain, and leg pain.  
**Nervous System/Psychiatric**  
Psychic disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, tremors, apathy, somnolence, anxiety, dream abnormalities, vertigo, paresthesia; and hemifacial dyesthesia.  
**Respiratory**  
Epistaxis, pharyngeal pain.  
**Skin**  
Rash and rarely, cases of severe generalized skin reactions including toxic epidermal necrolysis (TEN; some fatal), Stevens-Johnson syndrome, and erythema multiforme (some severe); purpura and/or petechiae (some with challenge); skin inflammation, urticaria, angioedema, pruritus, photosensitivity, alopecia, dry skin, and hyperhidrosis.  
**Special Senses**  
Tinnitus, taste perversion.  
**Ocular**  
Blurred vision, ocular irritation, dry eye syndrome, optic atrophy, anterior ischemic optic neuropathy, optic neuritis and double vision.  
**Urogenital**  
Interstitial nephritis (some with positive rechallenge), urinary tract infection, microscopic pyuria, urinary frequency, elevated serum creatinine, proteinuria, hematuria, glycosuria, testicular pain, and gynecomastia.  
**Hematologic**  
Rare instances of pancytopenia, agranulocytosis (some fatal), thrombocytopenia, neutropenia, leukopenia, anemia, leucocytosis, and hemolytic anemia have been reported.  
The incidence of clinical adverse experiences in patients greater than 65 years of age was similar to that in patients 65 years of age or less.  
Additional adverse reactions that could be caused by sodium bicarbonate, include metabolic alkalosis, seizures, and tetany.  
**OVERDOSAGE**  
Reports have been received of overdose with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience. (See ADVERSE REACTIONS.) Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdose is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdose, treatment should be symptomatic and supportive. As with the management of any overdose, the possibility of multiple drug ingestion should be considered. For current information on treatment of any drug overdose, a certified Regional Poison Control Center should be contacted. Telephone numbers are listed in the Physicians' Desk Reference (PDR) or local telephone book.  
Single oral doses of omeprazole at 1350, 1339, and 1200 mg/kg were lethal to mice, rats, and dogs, respectively. Animals given these doses showed sedation, ptosis, tremors, convulsions, and decreased activity, body temperature, and respiratory rate and increased depth of respiration.  
In addition, a sodium bicarbonate overdose may cause hypocalcemia, hypokalemia, hypernatremia, and seizures.

Revised: February 2006  
ZEGERID® is a registered trademark of Santarus, Inc. ©2006 Santarus, Inc.